Navigation Links
New Comprehensive Chromosome Screening Program at Pacific Fertility Center Refines Embryo Selection, Improves Pregnancy Rates
Date:3/6/2013

San Francisco, CA (PRWEB) March 06, 2013

Comprehensive Chromosome Screening (CCS) helps reduce multiple pregnancies and the risks that accompany them. It allows selection of high-quality embryos for transfer, which not only improves implantation rates for women, but also reduces miscarriage rates.

CCS uses advanced microarray technology to test chromosomes with more than 99 percent accuracy. It allows selection of high-quality embryos for transfer, which not only improves implantation rates, but also reduces miscarriage rates. And, because CCS reliably identifies high-quality embryos, patients don't have to "hedge their bets" by having several embryos transferred at one time.

In the past, it was difficult to know which embryos were of high quality. An embryo could look fine under the microscope, but have an abnormal number of chromosomes. In fact, when researchers examine the DNA within embryos, they find that 40–90 percent of normal-appearing embryos are genetically abnormal.

Earlier types of pre-implantation genetic testing had significant shortcomings. These tests involved removal (biopsy) of cells at an early embryo stage. Sampling of single cells at an early stage was not necessarily representative of the whole embryo, and thus certain abnormalities could be missed. Early biopsy also appeared to be detrimental to the health of some embryos.

With highly sensitive CCS techniques, it is now possible to test all 23 pairs of chromosomes in an embryo at a later stage, reliably and safely learning the exact number of chromosomes. This makes it possible to identify embryos with normal genetic structure and thus select the highest-quality embryos out of a group for transfer.

How does it work at cutting-edge facilities such as the Pacific Fertility Center (PFC)? PFC reports very high pregnancy rates in its patients undergoing in vitro fertilization (IVF) using this new type of pre-implantation genetic testing.

With CCS, PFC's average implantation rates are 76 percent in women under the age of 40 and 60 percent in those older than 40. Overall, two-thirds of PFC patients receiving an embryo selected with CCS have resulted in a pregnancy confirmed by ultrasound. Improving the chances of pregnancy, reducing the risk of miscarriage, and helping to produce one healthy baby at a time, are the priorities at PFC for all patients.

About Pacific Fertility Center
Pacific Fertility Center is an international destination for male and female fertility treatment and care. It provides an extensive array of fertility treatment options ranging from intrauterine insemination (IUI), intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) to cutting-edge technology such as vitrification and genetic testing of embryos. For more information: http://www.pacificfertilitycenter.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10475037.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. EASL publishes first comprehensive literature review on the burden of liver disease in Europe
2. South Charlotte Dentistry Initiates New Emphasis on Comprehensive Dental Treatment
3. Comprehensive maternal hemorrhage protocols improve patient safety
4. Portland Employers Provide Comprehensive Financial Education to Their Employees through National Non-Profit Speakers Bureau
5. Comprehensive public health approach urged to curb gun violence in US
6. Hospital of the University of Pennsylvania receives Comprehensive Stroke Center Certification
7. InShapeMD® Opens its Second Location in North Carolina to Provide Comprehensive Wellness for the Charlotte Community
8. Santa Rosa Orthopaedics Develops Hand Center for Comprehensive Hand and Upper Extremity Treatment
9. Audiology Associates Extends Comprehensive Tinnitus Testing and Treatment Program for Mill Valley Residents
10. Center For Sight Expands Services in University Park; David Hunt, O.D., Becomes Part of Center For Sight’s Comprehensive Eye Care Team
11. First comprehensive guidelines for managing anaplastic thyroid cancer published in Thyroid journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Indianapolis, IN (PRWEB) , ... February 08, 2016 ... ... serving the Indianapolis, IN metro area, has selected the latest beneficiary of their ... nonprofit organization dedicated to preventing bullying in area schools. Donations are now being ...
(Date:2/8/2016)... San Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... helped raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently ... who also was the American Cancer Society’s 2015 CEO of the Year , ...
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub some ... to Perry A~, author of “Calcium Bentonite Clay” the health benefits of integrating clay ... and detoxifying the body. , A former motivational speaker, Perry A~ has since dedicated ...
(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's document management ... DocuSyst provides a cloud hosted environment for FileHold software that is pay per ... 3rd party applications using the FileHold web services API. DocuSyst also advises clients ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... greater than 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth ... ”It is time to make a change in public health,” states Carole Baggerly, ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016  HemaFlo Therapeutics, Inc. announced today that the United ... Number 9,119,880 covering the use of NephroFlow to treat acute ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Peterson , PhD, HemaFlo,s founder, said, "We are pleased to ... --> Dale Peterson , PhD, HemaFlo,s founder, said, ...
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, Inc. ... genome editing, announced that the U.S. Food and ... New Drug (IND) application for SB-318, a single ... for Mucopolysaccharidosis Type I (MPS I). The SB-318 ... to initiate a Phase 1/2 clinical study (SB-318-1502) ...
(Date:2/8/2016)... , 8. Februar 2016  LivaNova, ... heute eine Infografik mit dem Titel „Epilepsy ... Welt), mit der der Krankheit gegenüber ein ... dazu ermutigen soll, Medikamentenresistenz bei Epilepsie auf ... allgemeinen Diskussion zu machen. Mithilfe der neuen ...
Breaking Medicine Technology: